Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of ...

As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
Medscape

Acute Renal Injury May Be Associated With mTOR Inhibitors

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...
Targeted Oncology

Gedatolisib Combinations Improve PFS in PIK3CA Wild-Type Advanced Breast Cancer

PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...
Cure Today

Treating EHE: What Are Your Options?

EHE treatment is highly individualized, involving surgery, ablation, chemotherapy, and mTOR inhibitors, depending on patient-specific factors. Next-generation sequencing helps identify genetic ...
BioWorld

Chinese scientists describe new PI3Kδ/mTOR inhibitors

Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...